Teva Pharmaceutical Finance Netherlands II B.V., established in the Netherlands, serves as a finance subsidiary of Teva Pharmaceutical Industries Ltd., headquartered in Israel. The company primarily focuses on raising funds through the issuance of bonds to support the broader financing needs of its parent organization and facilitate operational growth.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| TEVA 1.63% 2028-10-15 EURTeva Pharmaceutical Finance Netherlands II B.V. | Netherlands | 2028-10-15 | 1.625 | 3.12 |
| TEVA 3.75% 2027-05-09 EURTeva Pharmaceutical Finance Netherlands II B.V. | Israel | 2027-05-09 | 3.750 | 3.39 |
| TEVA 4.13% 2031-06-01 EURTeva Pharmaceutical Finance Netherlands II B.V. | Israel | 2031-06-01 | 4.125 | 3.81 |
| TEVA 4.38% 2030-05-09 EURTeva Pharmaceutical Finance Netherlands II B.V. | Israel | 2030-05-09 | 4.375 | 3.74 |
| TEVA 7.38% 2029-09-15 EURTeva Pharmaceutical Finance Netherlands II B.V. | Israel | 2029-09-15 | 7.375 | 3.75 |
| TEVA 7.88% 2031-09-15 EURTeva Pharmaceutical Finance Netherlands II B.V. | Israel | 2031-09-15 | 7.875 | 3.94 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Teva Pharmaceutical Finance Netherlands II B.V. commenced its bond issuance activities in 2016, with notable offerings designed to refinance existing debt and fund acquisitions, including critical strategic assets in the pharmaceutical sector. Recent bond issuances have continued to attract investor interest, with current yields reflecting competitive positioning within the industry. The company has also included unique features in its bonds, such as call options, providing flexibility and improving investment attractiveness amid changing market conditions.